BCMA-CAR T-cells are the most potent treatment against multiple myeloma. Here, we review the increasing body of clinical and correlative pre-clinical data that support their inclusion into first-line therapy and sequencing prior to T-cell-engaging antibodies. The ambition to cure multiple myeloma with (BCMA-)CAR T-cells is informed by genomic and phenotypic analysis that assess BCMA expression for patient stratification and monitoring, steadily improving early diagnosis and management of …